van der Meulen, N.P. Braccini, S. Eichler, R. Grundler, P.V. Hasler, R. Hirzel, W. Joray, S. Kiselev, D.C. Sobbia, R. Sommerhalder, A. Talip, Z. Zhang, H. JACoW Publishing Geneva, Switzerland 978-3-95450-205-9 10.18429/JACoW-Cyclotrons2019-TUA03 English 132-135 TUA03 target proton cyclotron radiation positron Contribution to a conference proceedings 2020 2020-06 https://doi.org/10.18429/JACoW-Cyclotrons2019-TUA03 http://jacow.org/cyclotrons2019/papers/tua03.pdf Paul Scherrer Institute runs a High Intensity Proton Accelerator (HIPA) facility, where a maximum of 100 µA protons is gleaned from high intensity 72 MeV protons from Injector 2, a separated sector cyclotron, into the IP2 target station. These protons irradiate various targets towards the production of exotic radionuclides intended for medical purposes. Many radiometals in use today are for the diagnosis of disease, with the most popular means of detection being Positron Emission Tomography. These positron emitters are easily produced at low proton energies using medical cyclotrons, however, development at these facilities are lacking. The 72 MeV proton beam is degraded at IP2 using niobium to provide the desired energy to irradiate targets to produce the likes of 44Sc, 43Sc, 64Cu and 165Er*,**,***. Once developed, these proofs-of-principle are then put into practice at partner facilities. Target holders and degraders require development to optimize irradiation conditions and target cooling. Various options are explored, with pros and cons taken into consideration based on calculations and simulations.